Cargando…
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic advances, it is still characterized by important unmet needs, thus remaining a challenging field of clinical research. The recent PARADIGM-HF trial compared the novel compound LCZ6...
Autores principales: | Filippatos, Gerasimos, Farmakis, Dimitrios, Parissis, John, Lekakis, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334585/ https://www.ncbi.nlm.nih.gov/pubmed/25849438 http://dx.doi.org/10.1186/s12916-015-0272-0 |
Ejemplares similares
-
PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015) -
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015) -
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015) -
LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021) -
LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)